CRISPR Therapeutics Announces New Gene Therapy Collaboration
Ticker: CRSP · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1674416
Sentiment: neutral
Topics: collaboration, licensing, gene-therapy
Related Tickers: CRSP
TL;DR
CRISPR Therapeutics inks new gene therapy deal, terms undisclosed.
AI Summary
CRISPR Therapeutics AG announced on June 26, 2025, that it has entered into a collaboration and license agreement with a third party. This agreement involves the development and commercialization of novel gene-edited cell therapies. Financial terms of the deal were not disclosed in this filing.
Why It Matters
This collaboration could accelerate the development of new gene-edited therapies for various diseases, potentially expanding CRISPR Therapeutics' pipeline and market reach.
Risk Assessment
Risk Level: medium — The risk level is medium due to the inherent uncertainties in drug development and the undisclosed financial terms of the collaboration, which could impact future revenue and expenses.
Key Players & Entities
- CRISPR Therapeutics AG (company) — Registrant
- June 26, 2025 (date) — Date of Report
FAQ
What is the nature of the collaboration announced by CRISPR Therapeutics AG?
CRISPR Therapeutics AG announced a collaboration and license agreement for the development and commercialization of novel gene-edited cell therapies.
When was this collaboration agreement announced?
The collaboration agreement was announced on June 26, 2025.
Are the financial terms of the collaboration disclosed in this filing?
No, the financial terms of the collaboration are not disclosed in this Form 8-K filing.
What is the primary business of CRISPR Therapeutics AG?
CRISPR Therapeutics AG is in the business of Biological Products (No Diagnostic Substances).
Where is CRISPR Therapeutics AG headquartered?
CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding CRISPR Therapeutics AG (CRSP).